COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
4.340
-0.010 (-0.23%)
At close: Aug 1, 2025, 4:00 PM
4.300
-0.040 (-0.92%)
After-hours: Aug 1, 2025, 7:38 PM EDT

Company Description

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.

The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc
COMPASS Pathways logo
CountryUnited Kingdom
Founded2020
IPO DateSep 18, 2020
IndustryMedical Care Facilities
SectorHealthcare
Employees166
CEOKabir Nath

Contact Details

Address:
33 Broadwick Street
London, W1F 0DQ
United Kingdom
Websitecompasspathways.com

Stock Details

Ticker SymbolCMPS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001816590
CUSIP Number20451W101
ISIN NumberUS20451W1018
SIC Code2834

Key Executives

NamePosition
Kabir Kumar Nath M.A., M.B.A.Chief Executive Officer and Director
Teri Loxam M.B.A.Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Guy GoodwinChief Medical Officer
Dr. Greg Ryslik Ph.D.Chief Technology Officer
Stephen D. SchultzSenior Vice President of Investor Relations
Anne BenedictChief People Officer
Lars Christian WildeSenior Advisor
Dr. Susan C. Stansfield Ph.D.Advisor
Dr. Michael Gold M.D., M.Sc.Chief Research and Development Officer
Lori Englebert M.B.A.Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 20258-KCurrent Report
Jul 31, 202510-QQuarterly Report
Jul 29, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 8, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 2025424B5Filing